Scancell IPO nets Oxford Capital 20% return

Venture capitalist Oxford Capital has seen the value of its holding in cancer vaccine specialist Scancell Holdings increase by 20 per cent following the company’s float on London’s PLUS Market

Marc Barber

Marc Barber

Marc was editor of GrowthBusiness from 2006 to 2010. He specialised in writing about entrepreneurs, private equity and venture capital, mid-market M&A, small caps and high-growth businesses.

Related Topics

Early Stage Funding